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Bleomycin-induced pneumonitis (BIP) is a serious and potentially fatal adverse effect of bleomycin.
Currently, BIP is treated on an empirical basis with high dose steroid. Pirfenidone is a new antiﬁbrotic
drug, which has been proven beneﬁcial in idiopathic pulmonary ﬁbrosis and is able to inhibit or reverse
BIP in animal models. Here, the ﬁrst two cases of human BIP treated with pirfenidone in addition to
steroid therapy are presented. Unfortunately, both patients died, which may be explained by the initi-
ation of therapy at a late stage. Therefore, studies of early or prophylactic treatment with pirfenidone in
relation to bleomycin-containing chemotherapy regimens are needed.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Bleomycin-induced pneumonitis (BIP) is a serious adverse effect
of bleomycin, which is used in chemotherapy regimens in patients
with testicular cancer or Hodgkin’s lymphoma [1]. The incidence of
BIP is 15e18% [2,3], and increasing age, low albumin level and the
use of granulocyte colony-stimulating factor have been associated
with the development of the condition [3]. BIP is diagnosed in the
presence of a combination of worsening pulmonary symptoms,
bilateral interstitial inﬁltrates on chest X-ray and/or computed to-
mography, or the presence of pulmonary ﬁbrosis on transbronchial
lung biopsy in the absence of infection [1]. Although similar 5-year
overall survival rates have been found in BIP patients compared to
unaffected patients, BIP has been associated with decreased sur-
vival in some studies [2,3], and the occurrence may necessitate
cessation of potentially life-saving chemotherapy.
There are no large or randomized studies regarding the treat-
ment of BIP, but traditionally, high-dose steroids have been used. In
animal studies, oxygen therapy has been associated with worse
outcome, and therefore, avoidance or at least minimization of ox-
ygen therapy is recommended [1]. New pharmacological treat-
ments are urgently needed.þ45 78 46 21 20.
k (E. Bendstrup).
Ltd. Open access under CC BY-NC-NDPirfenidone is a new anti-ﬁbrotic agent which has been proven
beneﬁcial for idiopathic pulmonary ﬁbrosis in humans [4]. It pos-
sesses both anti-inﬂammatory and anti-ﬁbrotic properties and has
been shown to slow or reverse bleomycin-induced pulmonary
ﬁbrosis in animals [5,6]. These characteristics suggest that pirfe-
nidone could be beneﬁcial for BIP in humans.
Here, we report two patients with testicular cancer and
bleomycin-induced fulminant pneumonitis in whom treatment
with a combination of pirfenidone and high-dose steroids failed.
Patient case 1
A 19-year old male with Down’s syndrome was diagnosed with
a retroperitoneal germinal cell tumor in May 2012. At diagnosis, a-
fetoproteinwas increased to 1973 mg/l. Renal functionwas impaired
with a glomerular ﬁltration rate (GFR) of 36 ml/min due to ureteral
compression. Pre-chemotherapy spirometry showed a forced
expiratory volume in 1 s (FEV1) of 2.29 l (68% of predicted) and a
forced vital capacity (FVC) 2.36 l (62%). The patient was treated
with three series of bleomycin 30.000 IU on day 2, 9 and 16, eto-
poside 100 mg/m2 s.i.d. on day 1e5 and cisplatin 20 mg/m2 s.i.d.
day 1e5. He was admitted to hospital with neutropenic fever after
the ﬁrst series, and started pegﬁlgatrim, a granulocyte-colony
stimulating factor, after the 2nd and 3rd series. After the 3rd se-
ries, he was again admitted with neutropenic fever and severe
desaturation. In spite of antibiotics and oxygen therapy, the patient
deteriorated, and after 2 days mechanical ventilation was license.
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and high dose Methylprednisolone 100 mg s.i.d. was initiated. C-
reactive protein and a-fetoprotein were both normalized, indi-
cating that the cancer had responded well to treatment. However,
the patient’s respiratory condition worsened, and one week after,
pirfenidone 802 mg t.i.d was initiated. In spite of maximal treat-
ment, the respiratory condition worsened and extra corporal
membrane oxygenation (ECMO) was started. After 2 weeks of
ECMO, 3 weeks of pirfenidone treatment and 4 weeks of high dose
steroids in combination with weekly steroid pulse courses, the
patient succumbed to BIP.
Patient case 2
A 42-year old mentally retarded male with schizophrenia was
diagnosed with disseminated testicular cancer in December 2012.
At diagnosis, a-fetoprotein was normal. The patient had impaired
renal function due to compression of the ureteres by retroperito-
neal tumor masses, and was treated with a nephrostomy catheter.
Hewas treated with 4 series of bleomycin 30.000 IU on day 2, 9 and
16, etoposide 100 mg/m2 s.i.d on day 1e5, and cisplatin 20 mg/
m2 s.i.d on day 1e5. A pulmonary function test prior to chemo-
therapy showed a slightly restrictive pattern with a mildly reduced
diffusion capacity. Due to hospital admittance with a neutropenic
fever after the ﬁrst series, hewas treatedwith pegﬁlgatrim after the
remaining chemotherapy series. After the 4th series, routine posi-
tron emission tomographyecomputed tomography (PETeCT)Fig. 1. High resolution computed tomography (HRCT) of patient 2 at diagnosis of bleomycin
show consolidations and bronchiectasis and the second HRCT shows severe progressio
bronchiectasis.showed interstitial pneumonitis compatible with bleomycin-
induced pneumonitis, and it came forward that the patient had
been experiencing progressive dyspnea and a dry cough for several
weeks. He was able to walk 420 m on 6 min walk test with desa-
turation to 94%. High dose Methylprednisolone 100 mg s.i.d. was
started, and pirfenidone treatment was considered, but abandoned
at this time. After one month of steroid treatment the patient was
admitted to hospital with a pulmonary infection and severe hyp-
oxia; a CT scan showed no evidence of pulmonary embolism, but
revealed interstitial changes (Fig. 1). The treatment was supple-
mented with pulse courses of steroid and pirfenidone 802 mg t.i.d.
but in spite of this, the patient’s condition deteriorated. Ventilator
treatment was initiated and followed by ECMO, but the patient died
from BIP two months after the diagnosis.
Discussion
We report here the ﬁrst two cases of fulminant bleomycin-
induced pneumonitis treated by pirfenidone. Disappointingly, pir-
fenidone did not seem to improve the clinical course.
In these two patients, treatment with granulocyte-colony
stimulating factor, neglect of dyspnea and renal impairment may
have contributed to the emergence of fatal BIP. The anti-
inﬂammatory and anti-ﬁbrotic actions of pirfenidone have been
shown to slow or even reverse the effects of bleomycin in animal
models [5,6]. In vitro, pirfenidone signiﬁcantly reduced surrogate
markers of ﬁbrosis such as the expression of TGFb-1 and-induced pneumonitis and 5 weeks later when pirfenidone was started. The ﬁrst HRCT
n with development of diffuse ground glass opacities, consolidations and traction
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manner, and human synovial ﬁbroblasts expressed less ICAM-1 in
the presence of pirfenidone. Pirfenidone also reduces expression of
other pro-ﬁbrotic genes such as collagen III [7]. It has antioxidant
effects and inhibits lipid peroxidation, and thus, pirfenidone may
function as a scavenger of reactive oxygen species [8].
The anti-ﬁbrotic action of pirfenidone has been compared with
that of prednisolone in bleomycin-induced ﬁbrosis in mice. Both
drugs were administered daily for approximately 30 days. Only
pirfenidone inhibited ﬁbrosis and suppressed the increase in pul-
monary levels of bFGF, TGFb1, stromal cell-derived factor 1a (SDF-
1a), IL-18 and IFNg, while both drugs attenuated the increase in
IL1b, IL-6, monocytes chemotactic protein (MCP)-1, and IL-12p40
(subunit of interleukin-12) [9,10]. The timing of pirfenidone treat-
ment has been studied in animal models, and the effect of pirfe-
nidone seems to be better when treatment is started
prophylactically or early after bleomycin treatment [6].
The bleomycin lung ﬁbrosis model in animals is widely used but
has limitations. More than 200 drugs have been tried in the bleo-
mycin mouse model but only pirfenidone have qualiﬁed for clinical
use. Bleomycin causes inﬂammation by overproduction of free
radicals and induction of pro-inﬂammatory cytokines and re-
sembles more an acute lung injury in the early phases. The sub-
sequent ﬁbrosis is developed after about 7 days and is partly
reversible. Thus, the slow and irreversible progressive of ﬁbrosis
seen in IPF is not reproduced in the bleomycin animal models,
which may explain the disappointing success rate of translating
results from the bleomycin model to IPF patients. It is also unclear
whether the bleomycin model in rodents can be translated to hu-
man bleomycin-induced pneumonitis, although it may intuitively
seem more plausible. Pirfenidone administered before or up to 7
days after bleomycin treatment will treat inﬂammation while pir-
fenidone administered more than 7 days after bleomycin targets
the ﬁbrotic pathways. Pirfenidone has shown beneﬁcial effects with
both scenarios although preventive treatment was the most efﬁ-
cient [6,11].
Therefore, the lack of effect on BIP in our patients may be due to
the initiation of therapy at a time when overt and fulminant BIP had
already developed. Thus, studies of early or prophylactic pirfenidonetreatment to clarify the role of pirfenidone in bleomycin-induced
pneumonitis and ﬁbrosis in humans are strongly needed.
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